About: Performance Evaluation of the PowerChek MERS (upE & ORF1a) Real-Time PCR Kit for the Detection of Middle East Respiratory Syndrome Coronavirus RNA

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Performance Evaluation of the PowerChek MERS (upE & ORF1a) Real-Time PCR Kit for the Detection of Middle East Respiratory Syndrome Coronavirus RNA Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Performance Evaluation of the PowerChek MERS (upE & ORF1a) Real-Time PCR Kit for the Detection of Middle East Respiratory Syndrome Coronavirus RNA
Creator	Ki, Chang-Seok Kim, Ji-Youn Kim, Jong-Won Lee, Myoung-Keun Huh, Hee Kwon, Hyeon Lee, Nam Yun, Sun
source	Medline; PMC
abstract	BACKGROUND: Molecular detection of Middle East respiratory syndrome coronavirus (MERS-CoV) using real-time reverse transcription (rRT)-PCR assays is the method of choice for diagnosis of MERS. We evaluated the performance of the PowerChek MERS (upE & ORF1a) real-time PCR Kit (PowerChek MERS assay; Kogene Biotech, Korea) a one-step rRT-PCR assay for the qualitative detection of MERS-CoV. METHODS: We evaluated PowerChek MERS assay performance in comparison with nested RT-PCR and sequencing of the RNA-dependent RNA polymerase (RdRp) and N genes. To evaluate diagnostic sensitivity and specificity, 100 clinical specimens (50 positive and 50 negative for MERS-CoV) were simultaneously tested by using the PowerChek MERS and sequencing assays. Assay performance, including limit of detection and precision, was evaluated in vitro by using MERS-CoV RNA transcripts. Analytical specificity was evaluated with a diverse collection of 16 respiratory virus–positive clinical specimens and 14 respiratory bacterial isolates. RESULTS: The 95% limits of detection of the PowerChek MERS assay for the upE and the open rading frame (ORF)1a were 16.2 copies/µL and 8.2 copies/µL, respectively. No cross-reactivity was observed. The diagnostic sensitivity and specificity of the PowerChek MERS assay were both 100% (95% confidence interval, 91.1–100%). CONCLUSIONS: The PowerChek MERS assay is a straightforward and accurate assay for detecting MERS-CoV RNA. The assay will be a useful tool for the rapid diagnosis of MERS and could prove especially important for MERS outbreak control.
has issue date	2017-08-16(xsd:dateTime)
bibo:doi	10.3343/alm.2017.37.6.494
bibo:pmid	28840986
has license	cc-by-nc
sha1sum (hex)	f92cd3c86281eee402ab60a75990ae6bb57b3c35
schema:url	https://doi.org/10.3343/alm.2017.37.6.494
resource representing a document's title	Performance Evaluation of the PowerChek MERS (upE & ORF1a) Real-Time PCR Kit for the Detection of Middle East Respiratory Syndrome Coronavirus RNA
has PubMed Central identifier	PMC5587821
has PubMed identifier	28840986
schema:publication	Ann Lab Med
resource representing a document's body	covid:f92cd3c86281eee402ab60a75990ae6bb57b3c35#body_text
is schema:about of	named entity 'KIT' named entity 'MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS RNA' named entity 'RRT-PCR' named entity 'DETECTION' named entity 'KIT' named entity 'METHOD' named entity 'REVERSE TRANSCRIPTION' named entity 'PCR ASSAY' named entity 'STEP' named entity 'Middle East respiratory syndrome' named entity 'MERS' named entity 'choice' named entity 'Middle East Respiratory Syndrome Coronavirus' named entity 'PERFORMANCE' named entity 'MERS' named entity 'KOREA' named entity 'PCR' named entity 'DETECTION' named entity 'MERS' named entity 'REAL-TIME PCR ' named entity 'PERFORMANCE' named entity 'FOR DIAGNOSIS' named entity 'REAL-TIME PCR ' named entity 'USING' named entity 'MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS' named entity 'REAL-TIME' named entity 'EVALUATION' named entity 'QUALITATIVE' named entity 'BACKGROUND' named entity 'MOLECULAR' named entity 'CHOICE' named entity 'EVALUATED' named entity 'ASSAY' covid:arg/f92cd3c86281eee402ab60a75990ae6bb57b3c35 named entity 'detection' named entity 'ORF' named entity 'asymptomatic' named entity 'rRT-PCR testing' named entity 'MERS' named entity 'MERS-CoV' named entity 'nucleic acid' named entity 'RdRp' named entity 'GAPDH' named entity 'RdRp' named entity 'fluorophores' named entity 'RNA sequences' named entity 'LOD' named entity 'MERS-CoV' named entity 'internal control' named entity 'MFDS' named entity '95%' named entity 'Germany' named entity 'Chicago' named entity 'Nucleic acid amplification' named entity 'glyceraldehyde-3-phosphate dehydrogenase' named entity 'RNA-dependent RNA polymerase' named entity 'PCR' named entity 'MERS' named entity 'fluorescein' named entity 'real-time PCR' named entity 'Bio-Rad' named entity 'lower respiratory' named entity 'PCR reaction' named entity 'lower respiratory' named entity 'MERS' named entity 'genome' named entity 'real-time' named entity 'MERS-CoV' named entity 'reverse transcription' named entity 'MERS-CoV' named entity 'MERS' named entity 'rRT-PCR' named entity 'reverse transcription' named entity 'MERS-CoV'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software